• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention

    4/13/23 2:54:17 PM ET
    $BBH
    $IBB
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BBH alert in real time by email
    • U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval of the abortion pill mifepristone. 
    • Garland said the administration "will be seeking emergency relief from the Supreme Court to defend the FDA's scientific judgment and protect Americans' access to safe and effective reproductive care."
    • The New Orleans-based 5th U.S. Circuit Court of Appeals put on hold part of last Friday's order by U.S. District Judge Matthew Kacsmaryk in Amarillo, Texas, while he hears a lawsuit by anti-abortion groups seeking to ban it.
    • The Planned Parenthood Federation of America condemned the 5th Circuit's decision as a rejection of science and law.
    • "The federal judiciary has — for the second time this week — rejected science and the law, and this time, the court decided they had the authority to re-write mifepristone's label," CNBC reported citing Alexis McGill Johnson, president of Planned Parenthood. 
    • "If allowed to stand, the consequences of this decision will be catastrophic not just for medication abortion access but the entire drug approval system," he added.
    • A U.S. federal appeals court has temporarily blocked a decision by a Texas judge. 
    • The abortion pill mifepristone will remain available in the U.S. for now but with some restrictions, including requiring in-person doctor visits to obtain the drug and limiting its use to the first seven weeks of pregnancy from the current ten, a federal appeals court ruled.
    Get the next $BBH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BBH
    $IBB
    $XBIO

    CompanyDatePrice TargetRatingAnalyst
    More analyst ratings

    $BBH
    $IBB
    $XBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Borisenko Grigory G.

    4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)

    1/5/26 5:00:02 PM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Dastoor Firdaus J.

    4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)

    1/5/26 5:00:05 PM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Kornberg Roger D.

    4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)

    1/5/26 5:00:04 PM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBH
    $IBB
    $XBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    VanEck Announces Year-End Distributions for VanEck Equity ETFs

    VanEck announced today the following 2025 annual distributions per share for its VanEck® equity exchange-traded funds. Distributions Per Share for the VanEck ETFs Listed Below Ex-Date: December 22, 2025 | Record Date: December 22, 2025 | Payable Date: December 26, 2025 Fund Ticker   Income Approximate % of Income from PFICs Short-Term Capital Gain Long-Term Capital Gain VanEck Africa Index ETF AFK $0.2716 5% None None VanEck Biotech ETF BBH $0.9565 None None None VanEck Gaming ETF BJK $1.3636 None None None VanEck Brazil Small-Cap ETF BRF $0.8889 1% None None VanEck Social Sentiment ET

    12/19/25 8:24:00 PM ET
    $BBH
    $BJK
    $ESPO

    VanEck Announces Year-End Distributions for VanEck Equity ETFs

    VanEck announced today the following 2024 annual distributions per share for its VanEck® equity exchange-traded funds. Distributions Per Share for the VanEck ETFs Listed Below Ex-Date: December 23, 2024 | Record Date: December 23, 2024 | Payable Date: December 24, 2024 Fund Ticker   Income Approximate % of Income from PFICs Short-Term Capital Gain Long-Term Capital Gain VanEck Africa Index ETF AFK None None None None VanEck Biotech ETF BBH $ 1.2517 22% None None VanEck Gaming ETF BJK $ 1.1667 34% None None VanEck Brazil Small-Cap

    12/20/24 8:56:00 PM ET
    $BBH
    $BJK
    $ESPO

    Altimmune Added to Nasdaq Biotechnology Index

    GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology Index (NASDAQ:NBI) effective prior to the market open on Monday, December 23, 2024. "Our addition to the NBI is an important recognition to conclude what has been a year of major progress for the Company," said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. "With a number of significant inflection points coming in 2025, including the topline data from the Phase 2b IMPACT trial of pemvidutide in MASH in the second quarter, we believe that we are well positioned heading into

    12/19/24 7:30:00 AM ET
    $ALT
    $IBB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBH
    $IBB
    $XBIO
    SEC Filings

    View All

    Xenetic Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)

    3/13/26 8:00:27 AM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Xenetic Biosciences Inc.

    10-K - Xenetic Biosciences, Inc. (0001534525) (Filer)

    3/12/26 5:00:51 PM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Xenetic Biosciences Inc.

    SCHEDULE 13G - Xenetic Biosciences, Inc. (0001534525) (Subject)

    2/12/26 2:15:28 PM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBH
    $IBB
    $XBIO
    Financials

    Live finance-specific insights

    View All

    VanEck Announces Year-End Distributions for VanEck Equity ETFs

    VanEck announced today the following 2025 annual distributions per share for its VanEck® equity exchange-traded funds. Distributions Per Share for the VanEck ETFs Listed Below Ex-Date: December 22, 2025 | Record Date: December 22, 2025 | Payable Date: December 26, 2025 Fund Ticker   Income Approximate % of Income from PFICs Short-Term Capital Gain Long-Term Capital Gain VanEck Africa Index ETF AFK $0.2716 5% None None VanEck Biotech ETF BBH $0.9565 None None None VanEck Gaming ETF BJK $1.3636 None None None VanEck Brazil Small-Cap ETF BRF $0.8889 1% None None VanEck Social Sentiment ET

    12/19/25 8:24:00 PM ET
    $BBH
    $BJK
    $ESPO

    VanEck Announces Year-End Distributions for VanEck Equity ETFs

    VanEck announced today the following 2024 annual distributions per share for its VanEck® equity exchange-traded funds. Distributions Per Share for the VanEck ETFs Listed Below Ex-Date: December 23, 2024 | Record Date: December 23, 2024 | Payable Date: December 24, 2024 Fund Ticker   Income Approximate % of Income from PFICs Short-Term Capital Gain Long-Term Capital Gain VanEck Africa Index ETF AFK None None None None VanEck Biotech ETF BBH $ 1.2517 22% None None VanEck Gaming ETF BJK $ 1.1667 34% None None VanEck Brazil Small-Cap

    12/20/24 8:56:00 PM ET
    $BBH
    $BJK
    $ESPO

    VanEck Announces Year-End Distributions for VanEck Equity ETFs

    VanEck announced today the following 2023 annual distributions per share for its VanEck® equity exchange-traded funds. Distributions Per Share for the VanEck ETFs Listed Below Ex-Date: December 18, 2023 | Record Date: December 19, 2023 | Payable Date: December 22, 2023 Fund Ticker   Income Approximate % of Income from PFICs Short-Term Capital Gain Long-Term Capital Gain VanEck Africa Index ETF AFK $0.3136 60% None None VanEck Biotech ETF BBH $0.7127 None None None VanEck Gaming ETF BJK $0.7111 6% None None VanEck Brazil

    12/15/23 7:57:00 PM ET
    $BBH
    $BJK
    $ESPO

    $BBH
    $IBB
    $XBIO
    Leadership Updates

    Live Leadership Updates

    View All

    Xenetic Biosciences, Inc. Announces Executive Leadership Transition

    Company's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA / ACCESSWIRE / May 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced the appointment of James Parslow, the Company's Chief Financial Officer, as interim Chief Executive Officer, effective May 16, 2024."I am a strong believer in the potential of our innovative immune-oncology technologies addressing hard-to-treat cancers. This management change will allow us to focus our resources on driving our pipeline toward

    5/22/24 5:00:00 PM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development

    Dr. Bissonnette brings over 25 years in small molecule and biotherapeutic drug discovery and development, oncology and inflammation research and regulatory expertiseFRAMINGHAM, MA / ACCESSWIRE / May 4, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it has engaged Reid P. Bissonnette, Ph.D. to serve as an executive consultant for translational research and development and to support the advancement of the Company's DNase-based oncology platform. Xenetic's DNase-based oncology platform is designed to target neutrophil extrace

    5/4/23 8:35:00 AM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison

    Mr. Cullison brings over 20 years of experience in the pharmaceutical industry with a broad range of expertise across business development and strategic planningFRAMINGHAM, MA / ACCESSWIRE / May 3, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it has engaged Scott N. Cullison to serve as an executive consultant for business development and to support the advancement of the Company's DNase-based oncology platform. Mr. Cullison brings over 20 years of experience in the pharmaceutical industry. He has amassed a broad range

    5/3/23 8:35:00 AM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBH
    $IBB
    $XBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Xenetic Biosciences Inc. (Amendment)

    SC 13D/A - Xenetic Biosciences, Inc. (0001534525) (Subject)

    3/18/24 1:45:06 PM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Xenetic Biosciences Inc. (Amendment)

    SC 13D/A - Xenetic Biosciences, Inc. (0001534525) (Subject)

    9/18/23 12:21:48 PM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Xenetic Biosciences Inc.

    SC 13D - Xenetic Biosciences, Inc. (0001534525) (Subject)

    6/15/23 5:20:05 PM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care